Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

Abstract Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors demonstrated activity in terms of progression-free survival (PFS) in advanced dedifferentiated liposarcoma (DD-LPS), a sarcoma with CDK4 amplification. CDK4 overexpression is by far more common than amplification in sarcomas and it might...

Full description

Bibliographic Details
Main Authors: Javier Martin-Broto, Jeronimo Martinez-Garcia, David S. Moura, Andres Redondo, Antonio Gutierrez, Antonio Lopez-Pousa, Javier Martinez-Trufero, Isabel Sevilla, Roberto Diaz-Beveridge, Maria Pilar Solis-Hernandez, Amancio Carnero, Marco Perez, David Marcilla, Jesus Garcia-Foncillas, Pablo Romero, Javier Fernandez-Jara, Daniel Lopez-Lopez, Ivan Arribas, Nadia Hindi
Format: Article
Language:English
Published: Nature Publishing Group 2023-10-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-023-01661-8

Internet

https://doi.org/10.1038/s41392-023-01661-8

Similar Items